VyndaMx® (Tafamidis), can prevent TTR from breaking up and forming amyloid fibrils. This medicine is used to treat wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy …

VYNDAQEL and VYNDAMAX are transthyretin stabilizers indicated for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults to reduce...

Aug 14, 2024 · The capsule is swallowed whole and should not be opened, crushed, or chewed. Always continue Vyndamax even if you do not feel changes in your symptoms right away.

Tafamidis is an oral medication for treating cardiomyopathy and peripheral neuropathy due to transthyretin amyloidosis (ATTR). It is a transthyretin stabilizer and has been shown to reduce …

Jul 25, 2024 · Tafamidis (brand names Vyndaqel and Vyndamax) is a transthyretin stabilizer that may be given to reduce death or hospitalization caused by heart problems in adults with cardiomyopathy …

Also find the prescribing information, announcements, resources, and channels to connect with Pfizer Medical.

Nov 7, 2025 · Tafamidis capsules (Vyndaqel, Vyndamax) must be swallowed whole and should not be opened, crushed, or chewed. Altering the capsules can compromise the medication's effectiveness …

The only once-daily capsule for ATTR cardiac amyloidosis* that offers proven reduction in CV mortality and CV-related hospitalization, a safety profile comparable to placebo,† and 5+ years of clinical and …

Feb 1, 2025 · Tafamidis is used to treat cardiomyopathy (enlarged and thickened heart muscle) of wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce death and …

If vomiting occurs after dosing, and the intact tafamidis capsule is identified, then an additional dose of tafamidis should be administered if possible. If no capsule is identified, then no additional dose is …